Generation Bio (NASDAQ:GBIO) Upgraded to Buy at Zacks Investment Research

Zacks Investment Research upgraded shares of Generation Bio (NASDAQ:GBIOGet Rating) from a hold rating to a buy rating in a research report report published on Tuesday morning, reports. Zacks Investment Research currently has $8.75 price target on the stock.

According to Zacks, “Generation Bio Co. is a genetic medicines company. It is focused on creating gene therapy for patients suffering from both rare and prevalent diseases. Generation Bio Co. is based in CAMBRIDGE, Mass. “

Separately, Needham & Company LLC reiterated a buy rating and issued a $27.00 price target on shares of Generation Bio in a research note on Tuesday, April 12th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from, the stock presently has a consensus rating of Buy and a consensus target price of $15.25.

Shares of Generation Bio stock opened at $6.68 on Tuesday. The business has a 50-day moving average of $6.28 and a 200-day moving average of $10.97. The company has a market capitalization of $380.77 million, a PE ratio of -3.17 and a beta of 3.31. Generation Bio has a 1-year low of $3.96 and a 1-year high of $38.86.

Generation Bio (NASDAQ:GBIOGet Rating) last posted its quarterly earnings results on Thursday, February 24th. The company reported ($0.54) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.57) by $0.03. As a group, sell-side analysts expect that Generation Bio will post -2.34 earnings per share for the current year.

A number of hedge funds and other institutional investors have recently modified their holdings of GBIO. Manchester Capital Management LLC bought a new position in Generation Bio in the third quarter worth about $25,000. Virginia Retirement Systems ET AL bought a new position in Generation Bio in the first quarter worth about $84,000. GSA Capital Partners LLP bought a new stake in shares of Generation Bio during the fourth quarter valued at approximately $126,000. Royal Bank of Canada boosted its position in shares of Generation Bio by 30.2% during the third quarter. Royal Bank of Canada now owns 5,698 shares of the company’s stock worth $143,000 after buying an additional 1,322 shares during the period. Finally, Wells Fargo & Company MN grew its holdings in Generation Bio by 2,831.9% in the 4th quarter. Wells Fargo & Company MN now owns 20,113 shares of the company’s stock worth $143,000 after buying an additional 19,427 shares in the last quarter. 82.42% of the stock is currently owned by hedge funds and other institutional investors.

Generation Bio Company Profile (Get Rating)

Generation Bio Co, a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases. The company provides a portfolio of programs, including programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology.

Featured Articles

Get a free copy of the Zacks research report on Generation Bio (GBIO)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Generation Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Generation Bio and related companies with's FREE daily email newsletter.